3,826 reports of this reaction
1.3% of all NATALIZUMAB reports
#20 most reported adverse reaction
MOBILITY DECREASED is the #20 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 3,826 FDA adverse event reports linking NATALIZUMAB to MOBILITY DECREASED. This represents approximately 1.3% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience mobility decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOBILITY DECREASED is a less commonly reported adverse event for NATALIZUMAB, but still significant enough to appear in the safety profile.
In addition to mobility decreased, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to mobility decreased in FDA adverse event reports:
MOBILITY DECREASED has been reported as an adverse event in 3,826 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOBILITY DECREASED accounts for approximately 1.3% of all adverse event reports for NATALIZUMAB, making it a notable side effect.
If you experience mobility decreased while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.